Avinash Vallurupalli, DO
Nephrology · Fort Worth, TXNPI 1457553224
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Amgen at 31.8% of the total.
Across 151 payments — averaging $23.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$431
- Bayer$424
- Vifor Pharma, Inc.$411
- Veloxis Pharmaceuticals, Inc.$158
- Medtronic$106
- plus $940 from 23 others
What the payments were for
- Food & beverage$3,50497%
- Education$1173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 40 | $1,152 |
| AstraZeneca(2 entities) | 23 | $431 |
| Bayer | 20 | $424 |
| Vifor Pharma, Inc. | 16 | $411 |
| Veloxis Pharmaceuticals, Inc. | 2 | $158 |
| Medtronic | 2 | $106 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Aurinia Pharma U.S., Inc. | 4 | $83 |
| Travere Therapeutics, Inc. | 3 | $77 |
| Boehringer Ingelheim | 3 | $73 |
| Akebia Therapeutics Inc | 3 | $64 |
| Philips North America LLC | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Calliditas Therapeutics US Inc. | 2 | $44 |
| Bard Peripheral Vascular, Inc. | 3 | $42 |
| Boston Scientific | 2 | $42 |
| Cook Medical LLC | 3 | $40 |
| Ultragenyx Pharmaceutical Inc. | 2 | $37 |
| Novo Nordisk | 2 | $34 |
| Sobi, Inc | 1 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Fresenius USA Marketing, Inc. | 2 | $29 |
| GSK | 2 | $28 |
| W. L. Gore & Associates, Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $18 |
| OPKO Pharmaceuticals, LLC | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,621 in reported general payments places this provider in the 65th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 66 | $53,937 |
| VeltassaPatiromer Calcium Sorbitex | 30 | $29,776 |
| KerendiaFinerenone | 32 | $27,157 |
| Sevelamer Carbonate | 55 | $16,642 |
| EliquisApixaban | 15 | $13,551 |
| Calcium Acetate | 33 | $3,337 |
| Nifedipine ErNifedipine | 48 | $2,068 |
| Hydralazine Hcl | 100 | $1,078 |
| Clonidine | 13 | $852 |
| Furosemide | 81 | $676 |
| Midodrine Hcl | 11 | $609 |
| Amlodipine Besylate | 77 | $604 |
| Carvedilol | 62 | $525 |
| Klor-ConPotassium Chloride | 11 | $459 |
| Calcitriol | 24 | $394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $431 | $53,93766 claims |
| BayerKerendia | $424 | $27,15732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,070 nephrology providers in Texas.
Other nephrology in Fort Worth
- Saravanan BalamuthusamyFort Worth$435K
- Sandeep ShoriFort Worth$195K
- Michael AragonFort Worth$138K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.